Trial Profile

A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
13 Sep 2023 Results of pooled analysis from SURPASS 1-5 and Japan-mono, and Japan-combo assessing pharmacokinetics, efficacy and safety published in the Journal of Clinical Endocrinology and Metabolism
01 Apr 2023 Results of post-hoc analysis of SURPASS-1, -3, -4, -5, J-mono and J-combo assessing safety and efficacy of tirzepatide in type 2 diabetes, published in the Diabetes, Obesity and Metabolism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com